KM KRX:083550KOSDAQ

케이엠 · Korean news coverage and regulatory filings, organized.

Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11

In Q2 2026, KM reported revenue of ₩39.6bn, up 18.3% year on year, and operating profit of ₩928m. KM (케이엠) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 1 article. The most common catalyst was clinical & approvals (1).

KM quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩39.6bn+18.3%₩928m₩797m
Q1 2026₩33.8bn+8.2%−₩928m−₩231m
Q4 2025 derived₩36.2bn+7.0%−₩615m₩2.3bn
Q3 2025₩34.5bn+0.8%₩1.7bn₩1.8bn
Q2 2025₩33.4bn+4.8%₩101m₩1.4bn
Q1 2025₩31.3bn+0.3%−₩1.5bn−₩1.3bn
Q4 2024 derived₩33.8bn+0.4%−₩1.4bn−₩1.2bn
Q3 2024₩34.2bn+12.7%₩285m₩3m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

KM top stories 2 weeks, by number of outlets

  1. 1
    KM Pharmaceutical Surges Despite Delisting; SK Biopharm Falls on FDA Hold [K-Bio Pulse]
    1 outlets · 1 articlesFirst report Sep 15 08:28 이데일리Regulatory approval

Latest KM news Korean headlines